Toreador Therapeutics

Toreador Therapeutics is a private, preclinical biotechnology company based in San Francisco developing next-generation selective T cell engager therapeutics. The company combines a proprietary T cell engager platform with DNA-based super-resolution microscopy to identify biologically tuned target combinations and engineer dual- and triple-targeted therapeutics with improved selectivity. Its approach is being applied primarily in oncology, with additional stated relevance for autoimmune and inflammatory diseases. Toreador also describes the platform as adaptable across multiple antibody-related modalities, including T cell engagers, bispecific or multispecific antibodies, antibody-drug conjugates, and radiopharmaceuticals. The company appears to remain independent and privately held.